A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Phase 1 of this study will evaluate the safety and tolerability of 177Lu-FAP-2286 and
determine the recommended Phase 2 dose (RP2D) in patients with advanced solid tumors. Phase 2
of this study is designed to evaluate objective response rate (ORR) in patients with specific
solid tumors.